Charles Samson

Medicine & Life Sciences

1. Inflammatory Bowel Diseases 100%
2. Pediatrics 69%
3. Pediatric Crohn's disease 62%
4. Crohn Disease 55%
5. Hepatocytes 45%
6. Infliximab 35%
7. Granulocyte-Macrophage Colony-Stimulating Factor 33%
8. Pragmatic Clinical Trials 30%
9. Ulcerative Colitis 29%
10. Apoptosis 27%
11. Ileitis 23%
12. Child 23%
13. NF-kappa B 22%
14. Quality Improvement 22%
15. Ileal Diseases 20%
16. Multicenter Studies 19%
17. Budesonide 18%
18. Learning Health System 17%
19. Adrenal Cortex Hormones 16%
20. Smad Proteins 15%
21. Patient Reported Outcome Measures 15%
22. Closed Head Injuries 14%
23. Histoplasmosis 14%
24. Adalimumab 13%
25. Anti-Inflammatory Agents 13%
26. Growth Plate 13%
27. Obstructive Jaundice 13%
28. Juvenile Arthritis 12%
29. Growth 12%
30. Autoantibodies 12%
31. Colitis 12%
32. Electronic Health Records 12%
33. Information Systems 11%
34. Non-alcoholic Fatty Liver Disease 11%
35. Methotrexate 11%
36. Transforming Growth Factors 11%
37. Registries 10%
38. Gastroenterology 10%
39. Bile Ducts 9%
40. Clinical Decision Support Systems 9%
41. Tumor Necrosis Factor-alpha 9%
42. Carrier Proteins 9%
43. Prescriptions 9%
44. Immunosuppressive Agents 8%
45. Young Adult 8%
46. Case-Control Studies 8%
47. Hospital Emergency Service 8%
48. Cell Cycle 8%
49. Down-Regulation 8%
50. Necrosis 8%